Over 6 months, 23.2% of patients receiving rifaximin monotherapy experienced an OHE breakthrough episode compared with 49% of patients receiving lactulose monotherapy (P<0.0001), reported Jasmohan S.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fewer patients treated with rifaximin had an overt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback